Background Balloon-expandable coronary-artery stents were developed to prevent coronary
restenosis after coronary angioplasty. These devices hold coronary vessels open at sites …

Background Angiotensin-converting enzyme (ACE) inhibitors may exert some of their benefits
in the therapy of hypertension, congestive heart failure, and acute myocardial infarction by …

Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary syndromes
and/or undergoing percutaneous coronary interventions. Clopidogrel, in combination with …

Background Clopidogrel and aspirin are the most commonly used antiplatelet therapies for
percutaneous coronary intervention (PCI). We assessed the effect of various clopidogrel and …

ContextPercutaneous coronary intervention (PCI) is associated with excellent short-term
improvements in ischemic symptoms, yet only three fifths of PCI patients at 5 years and one …

Background The multicentre, randomised Benestent-II study investigated a strategy of
implantation of a heparincoated Palmar-Schatz stent plus antiplatelet drugs compared with the …

Background New-generation coronary stents that release zotarolimus or everolimus have
been shown to reduce the risk of restenosis. However, it is unclear whether there are …

Objectives : We compared the risk of stent thrombosis (ST) after drug-eluting stents (DES)
versus bare-metal stents (BMS), and tested the hypothesis that the risk of DES thrombosis is …

To assess platelet function profiles in diabetic and nondiabetic patients on aspirin and
clopidogrel therapy, two patient populations were included to investigate the 1) acute effects of a …

Background— The effect of β-blockers on infarct size when used in conjunction with primary
percutaneous coronary intervention is unknown. We hypothesize that metoprolol reduces …